CA2125402A1 - Process for insolubilizing n-carboxyalkyl derivatives of chitosan - Google Patents
Process for insolubilizing n-carboxyalkyl derivatives of chitosanInfo
- Publication number
- CA2125402A1 CA2125402A1 CA002125402A CA2125402A CA2125402A1 CA 2125402 A1 CA2125402 A1 CA 2125402A1 CA 002125402 A CA002125402 A CA 002125402A CA 2125402 A CA2125402 A CA 2125402A CA 2125402 A1 CA2125402 A1 CA 2125402A1
- Authority
- CA
- Canada
- Prior art keywords
- chitosan
- carboxyalkyl
- film
- set forth
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
Abstract
A method for insolubilizing films of N-carboxyalkyl derivatives of chitosan uses an annealing process to provide materials which can have varied degradation times. These materials can be used for various biomedical applications such as adhesion prevention. The annealing process heats the film for predetermined times at predetermined temperatures to vary the solubility of the film.
Description
~12~402 PROCESS FOR INSOLUBILIZING N-CARBOXYALKYL
~ERIVATIVES OF CHITOSAN
.
BACKGROUND :)F THE INVENTION
Field of the Invention The present invention relates to a rr~ethod of temporarily insolubilizing 10 films and gels of N-carboxyalkyl derivatives of chitosan to provide materials which can have varied degradation times for various biomedical applications such as adhesion prevention. More particularly, the method relates to an annealing process in which the material is insolubilized by exposing film to temperatures between 50C and 200C for various lengths of time.
ûescriPtion of the Prior Art Chitin and chitosan (partially deacetylated chitin) are well known biocompatiblematerials whose preparation has been described in U.S. Patent 2,040,880, which issued on May 19, 1936. A derivative of chitosan, N,O-carboxymethyl chitosan, and its 20 produ~tion ha~ been described in U.S. Patent 4,6i9,995~ which issued to E.R. Hayes in Octooer of 1986~ The preparation of another chitosan derivative, N-carboxybutyl chitosan, is described in U.S. Patent 4,835,265.
The uses of chitin, chitosan, and other polysaccharides in biomedical applications is most evident in wound dressings. Materlals for use in wound dressing applications 25 are disclosed in U.S. Patents 3,632,754, 4,532,134, 4,659,700, 4,572,g06, 4,378,017, foreign patents G8 2026~16, EP 0200574 and publications WO 86/009t2 and WO 87/07618. Others have addressed the problem of adhesion prevention utilizing biodegradable materials. U.S. Patent 4,603,69~, which issued August 5,1986 to Ikada et al, discloses the use of an absorbable polyester polymer~ (: hitin and Chitosan can 3Q be absorbed by hydrolysis in vivo.
Co-pending applicatlon Serial No~ 07/644,758, filed on ~anuary 24, 1991 (U~S~
Patent 5,Q93,319) and assisned to the assignee of the present invention, teaGhes the use of chitosan and derivatives thereof for adhesion prevention. None of these patents or patent applications, teach a simple way of insolubilizing films and gels from35 derivatives of chitin for intemal application to vary degradation times~
~U~STITUTE S~EET
c - - .
? 212 ~ 4 0 2 As described in co-pending application Serial No. 07/644,758, scar tissue results from the organization of fibrinous exudate on tissue surfaces due to the infliction of trauma or inflammation. Vital tissues such as blood vessels, or organs including the kidney, liver, and intestines are coated with mucous or serous membranes so that they can function independently of each other. Examples of the mucous or serous membranes are the body wall pleura and the organ pleura in the thoracic cavity and the parietal peritoneum and mesentery in the abdominal cavity, each protecting the corresponding organs. Surgical trauma or inflammation in those portions of the body coated with serous membranes could result in the build up of fibrinous exudate 10 regardless of the size of the affected part. This ultimately causes the creation of organized fibrin many times referred to as scarring or adhesions. Such adhesionsbetween these tissues may be observed in all tissues of the body, not just thosementioned above~ Scarring between tissues can lead to severe pain, decreased function, and even permanent loss of motility.
Adhesions occur in the orthopedics field where conditions such as acute or chronic arthritis, suppurative, rheumatoid, gonorrheal, or tuberculous arthritis, or traumatic injuries at the joint, such as fracture or sprain, result in ankylotic diseases wherein the surface of the bones constituting the joint adhere to ~ach other and thereby restrict the mobility of the joint. In addition, congenital radioulnar syntosis, wherein a 2Q spoke bone and an ulna adhere together, is difficult to remedy by a surgical operation, since the separated bones frequently re-adhere. Adhesions are also prominent in tendon surgery. In this instance, there is a general tendency towards adhesion betNeen the tendon and the surrounding sheath or other surrounding tissue during an immobilization period following the operation.
More recently, there has been increased interest in the prevention of the "laminectomy membrane" which forms following spinal laminectomy procedures. The laminectomy membrane is a well oryanized mass of fibrinous tissue which replaces the bone that was`'removed at the laminectomy~ This fibrinous mass binds the dura to the overlying muscles~ This causes narrowing of the spinal canal which places pressure 30 on the cauda equina or nerve roots~ This scar tissue formation rnay require reoperation which is tedious and dangerous leading to the possibility of dural tears and the damage to the emergent nerve roots resulting in motor weakness, sensory change, and painful paresthesia~
SUBSTlTUTE S~E~
~ 2125402 Num0rous papers have been published on the various treatments to prevent scar tissue build up. Treatments such as liquid paraffln, camphor oil, chondroitin sulfate, and urea exhibit an insufficient effect since they function only temporarily. Other prophylactic treatments such as silicone membranes, gutta percha, or poly (tetra-5 fluoroethylene) membranes have been used to serve as barriers to adhesion formation.
However, these materials are inert and will, therefore, remain in the body and many times be recogni2ed as a foreign body. Therefore, a second operation may be necessary to remove the barrier material.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a process for producing modified N~arboxyalkyl derivatives of chitosan for the prevention of fibrinous exudate build-up, which degrades in vivo in various predetermined time periods~
It is a further object of the invention to provide a slmple annealing process for insolubilizing N-carboxyalkyl derivatives of chitosan.
Accordingly, these and related objects are achieved by a process for insolubilizing films of N-carboxyalkyl denvatives of chitosan. The N-carboxyalkyl derivative of chitosan is dissolved in a neutral pH aqueous solution or a slightly acidic solution.
20 The solution is then cast and dried to form a thin clear film. Alternatively, the solution is poured into a mold (for example a petri dish) and Iyophilized to forrn a sponge-type film with varying dimensions depending on the mold, the solution concentration, and the solution volume. The resulting films are insolubiîized by an annealing process in which they are exposed to temperatures between 50C and 25 200C for various periods of time depending on the desired length of insolubilizattori time, and uitimately bioresorption time.
rnese and other objects and advantages of the presen~ invention will become apparent from the following detailed description which discloses several embodtments of the invention~ It is to be understood that the examples used are for the purposes of 30 illustration only, and not as a deflnition of the inventton.
`- 2125~02 .
~ERIVATIVES OF CHITOSAN
.
BACKGROUND :)F THE INVENTION
Field of the Invention The present invention relates to a rr~ethod of temporarily insolubilizing 10 films and gels of N-carboxyalkyl derivatives of chitosan to provide materials which can have varied degradation times for various biomedical applications such as adhesion prevention. More particularly, the method relates to an annealing process in which the material is insolubilized by exposing film to temperatures between 50C and 200C for various lengths of time.
ûescriPtion of the Prior Art Chitin and chitosan (partially deacetylated chitin) are well known biocompatiblematerials whose preparation has been described in U.S. Patent 2,040,880, which issued on May 19, 1936. A derivative of chitosan, N,O-carboxymethyl chitosan, and its 20 produ~tion ha~ been described in U.S. Patent 4,6i9,995~ which issued to E.R. Hayes in Octooer of 1986~ The preparation of another chitosan derivative, N-carboxybutyl chitosan, is described in U.S. Patent 4,835,265.
The uses of chitin, chitosan, and other polysaccharides in biomedical applications is most evident in wound dressings. Materlals for use in wound dressing applications 25 are disclosed in U.S. Patents 3,632,754, 4,532,134, 4,659,700, 4,572,g06, 4,378,017, foreign patents G8 2026~16, EP 0200574 and publications WO 86/009t2 and WO 87/07618. Others have addressed the problem of adhesion prevention utilizing biodegradable materials. U.S. Patent 4,603,69~, which issued August 5,1986 to Ikada et al, discloses the use of an absorbable polyester polymer~ (: hitin and Chitosan can 3Q be absorbed by hydrolysis in vivo.
Co-pending applicatlon Serial No~ 07/644,758, filed on ~anuary 24, 1991 (U~S~
Patent 5,Q93,319) and assisned to the assignee of the present invention, teaGhes the use of chitosan and derivatives thereof for adhesion prevention. None of these patents or patent applications, teach a simple way of insolubilizing films and gels from35 derivatives of chitin for intemal application to vary degradation times~
~U~STITUTE S~EET
c - - .
? 212 ~ 4 0 2 As described in co-pending application Serial No. 07/644,758, scar tissue results from the organization of fibrinous exudate on tissue surfaces due to the infliction of trauma or inflammation. Vital tissues such as blood vessels, or organs including the kidney, liver, and intestines are coated with mucous or serous membranes so that they can function independently of each other. Examples of the mucous or serous membranes are the body wall pleura and the organ pleura in the thoracic cavity and the parietal peritoneum and mesentery in the abdominal cavity, each protecting the corresponding organs. Surgical trauma or inflammation in those portions of the body coated with serous membranes could result in the build up of fibrinous exudate 10 regardless of the size of the affected part. This ultimately causes the creation of organized fibrin many times referred to as scarring or adhesions. Such adhesionsbetween these tissues may be observed in all tissues of the body, not just thosementioned above~ Scarring between tissues can lead to severe pain, decreased function, and even permanent loss of motility.
Adhesions occur in the orthopedics field where conditions such as acute or chronic arthritis, suppurative, rheumatoid, gonorrheal, or tuberculous arthritis, or traumatic injuries at the joint, such as fracture or sprain, result in ankylotic diseases wherein the surface of the bones constituting the joint adhere to ~ach other and thereby restrict the mobility of the joint. In addition, congenital radioulnar syntosis, wherein a 2Q spoke bone and an ulna adhere together, is difficult to remedy by a surgical operation, since the separated bones frequently re-adhere. Adhesions are also prominent in tendon surgery. In this instance, there is a general tendency towards adhesion betNeen the tendon and the surrounding sheath or other surrounding tissue during an immobilization period following the operation.
More recently, there has been increased interest in the prevention of the "laminectomy membrane" which forms following spinal laminectomy procedures. The laminectomy membrane is a well oryanized mass of fibrinous tissue which replaces the bone that was`'removed at the laminectomy~ This fibrinous mass binds the dura to the overlying muscles~ This causes narrowing of the spinal canal which places pressure 30 on the cauda equina or nerve roots~ This scar tissue formation rnay require reoperation which is tedious and dangerous leading to the possibility of dural tears and the damage to the emergent nerve roots resulting in motor weakness, sensory change, and painful paresthesia~
SUBSTlTUTE S~E~
~ 2125402 Num0rous papers have been published on the various treatments to prevent scar tissue build up. Treatments such as liquid paraffln, camphor oil, chondroitin sulfate, and urea exhibit an insufficient effect since they function only temporarily. Other prophylactic treatments such as silicone membranes, gutta percha, or poly (tetra-5 fluoroethylene) membranes have been used to serve as barriers to adhesion formation.
However, these materials are inert and will, therefore, remain in the body and many times be recogni2ed as a foreign body. Therefore, a second operation may be necessary to remove the barrier material.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a process for producing modified N~arboxyalkyl derivatives of chitosan for the prevention of fibrinous exudate build-up, which degrades in vivo in various predetermined time periods~
It is a further object of the invention to provide a slmple annealing process for insolubilizing N-carboxyalkyl derivatives of chitosan.
Accordingly, these and related objects are achieved by a process for insolubilizing films of N-carboxyalkyl denvatives of chitosan. The N-carboxyalkyl derivative of chitosan is dissolved in a neutral pH aqueous solution or a slightly acidic solution.
20 The solution is then cast and dried to form a thin clear film. Alternatively, the solution is poured into a mold (for example a petri dish) and Iyophilized to forrn a sponge-type film with varying dimensions depending on the mold, the solution concentration, and the solution volume. The resulting films are insolubiîized by an annealing process in which they are exposed to temperatures between 50C and 25 200C for various periods of time depending on the desired length of insolubilizattori time, and uitimately bioresorption time.
rnese and other objects and advantages of the presen~ invention will become apparent from the following detailed description which discloses several embodtments of the invention~ It is to be understood that the examples used are for the purposes of 30 illustration only, and not as a deflnition of the inventton.
`- 2125~02 .
4- . .
DESCRIPTION OF THE PREFERRED EMBODIMENT
The biodegradable polymer films to be used to inhibit fibrin fomlation and organization are materials which will eventually revert to the gel or solution state 5 and ultimately be resorbed and metabolized by the body. As taught in co-pending application Serial Number 07/644,758, these materials include amino N-carboxyalkyl derivatives of chitosan. Chitosan is a partially deacetylated chitin defined for the purposes herein as being greater than 50% deacetylated.
The N~arboxyalkyl derivatives used in the present invention are water soluble 10 polymers which have not been crosslinked to form insoluble materials. Specific examples of these materials are N-carboxymethyl chitosan, N~arboxybutyl chitosan, N,O carboxymethyl chitosan, and N,O-carboxybutyl chitosan, N-carboxy-ethyl chitosan, N,O-carboxyethyl chltosan, N,O-carboxypropyl chitosan, sulfated N-carboxyalkyl chitosan and N-carboxypropyl chitosan. However, these materials can be temporarily 15 insolubilized to form substances which will begin to degrade in a period of from 2-5 days to up to one year in vitto. It has been found that exposure of films of these materials to heat from 50C to 200C for various time periods varies the insolubilization time and ultimately the bioresorption time. In general, the higher the temperature of exposure and the longer the time of exposure, the greater the time to solubilize the film.
20 In order to vary the degradation time, the temperature and the length of time of heat exposure are varied from 50 - 200C anywhere from 20 minutes to 24 hours but could be as little as 10 minutes and preferably 10 minutes to ~ hours.
These materials are prepared from natural products or by ferrnentation methods ~;as described in U.S. Patents 4,835,265 and 4,619,995. The molecular weight of the 25 b~odegradable N-carboxyalkyl derivatives of chitosan for use in the present invention preferably range from 1,0Q0 daltons to 3,000,000 daltons.
In the preferred embociiment, these polymers would be in the form of a film, sponge, or woven sheet which will break down into visco-elasffc matenals. Examples .
of these would be the use of N,~carboxymethyl chitosan or N-carboxy-butyl chitosan ~30 films insolubilized by annealing with heat as described herein. While the exact -~ mechanism which causes the insolubillzation of the materials is unclear, it is postulated that either a dehydration mechanism, or a crystallization mechanism or a combination of the two is causing this phenomena. Additives such as anff-thrombogenic materiais, such as heparin or the like, may be added to the films before insolubilizing.
5~ Tl~E SHEE~
,~ ' '~'' '; ; ;
212`~02 -5- .
As described in co-pending application 07/644,758, it is also possible to form these materials into a viscous gel for injection into the affected location to prevent fibrinous buildup. This gel could be used for applications where a shorter ln vlvo residence time is desired and/or the location would best be suited for prevention 5 of adhesions with a material in this form. The gels may be formed by placing the insolubilized films in a sterile aqueous media and heating the solution to increased temperatures until the film hydrates and swells to form a gelatinous mass.
Again, as with the film, the degree of insolubilization of the viscous gels can be varied by varying the temperature of the aqueous solution and the extent of time 10 the film is allowed to remain in the solution.
The present invention has the added advantage that the insolubilization step canbe done during the heat or steam sterilization of the device, if desired. For example, the film may be insolubilized during the autoclave sterilization of the device at a temperature greater than 1 20C for a standard autoclave cycle.
The invention will now be described in further detail with reference being made to the following examples. It should, however, be recognized that the examples are given as being illustrative of the present invention and are not intended to define the spirit and spirit thereof.
20 Exam~le 1 . . .
One gram of medical grade N,O-carboxymethyl chitosan (NOVA Chern, Nova Scotia) was dissolved in 100 cc of purified water. The resulting 1% solution wasthen flltered through a series of cellulose membranes (12, 8, 0.45 micrometer) to remove all insoluble matter. The solution was then recirculated over and through a 0.5 25 micron tangential flow membrane which was specially treated with polypeptides specific for removal of pyrogen and other hydrophobic impurities (Catalog number 4200 -AlerChek, Portland, ME) for a period of approximately one hour on tangenttal flow ultra-flltration device (Filtron Non~ood, MA). The resumng solution was then rendered ~
of all low molecular weight impurities by extensive dialysis with water via a 300K
; 30 rnolecular weight cutoff membrane (Filtron - Norwood, MA) on the same ultra-filtration device.
Films were then formed from this solution by both casting (allowing evaporation)on a non-stick surface such as a glass petrii dish, or a plece of mylar fi1m and by freeze SUBgrITUl-E S~E~
drying by adding 300 ml of the solution to a 90 rnm diameter disposable petri dish and Iyophilized in a tray dryer for 72 hours a~ -50C. The resulting films (either cast or freeze dried~ were then insolubilized by placing the film into an oven at 121C for 20 minutes (correlating to a standard autoclave cycle). Both films were placed in aqueous media and dissolved within 5 days. Based on the dissolution which did occur, the film would dissolve in approximately two months.
Example 2 Three films were prepared as descnbed above in Example 1 by casting in a petri dish. Each was exposed to a different temperature for a period of 30 minutes. The first was heated at 76C, the second at 121C and the third.at 168C. One film was cast and not treated. This served as a control.
The four films were placed in ~ cc of PBS and placed in an incubator at 37C.
At various times, the samples were removed and obseNed yisually for solubility.
Followirig this the incubation medium was removed from the dish and analyzed forsoluble product via size exclusion chromatography. The control film was completely solubilized within one day. The film at 76C indicated complete solubility between 1-2 days. The 121 C treated film indicated complete solubility at 4-5 days, while the film treated at 168C indicated no evidence of solubility up to 14 days~
ExamPle ~
Three films were prepared as described above in Example 1 with the exception that the temperature of annealing was kept constant at 121C and the exposure time was varied between 15 minutes and 23 hours. Again, a non-treated film ser~Jed as a control. All films were evaluated as mentioned above.
The film treated at 15 minutes indicated complete solubility in 2-3 days, the film treated for 60 minutes indicated solubility through 14 days (complete solubility had not yet been attairied) while the film treated at 2 hours indicated no solubility in an excess of 14 days.
Thus the degradation of the films in wvo could be lengthened by increasing the annealing time and temperature. For a typical orthopedic application, a film which would degrade within 14 days is desirable and may be attained by annealing at 121C
for about 60 minutes~
TITl,~TF S~
2i25~02 The material of the present invention may be used in a nnethod for preventing adhesions between soft intemal body tissue by first preparing an aqueous solution of N-carboxyalkyl derivatives of chitosan, then forming a film from the aqueous solution by removing water therefrom and then insolubilizing the film by heating the film at a 5 temperature of at least 70C for a minimum of 15 minutes and placing the film between the tissues after being insolubilized.
While several examples of the present invention have been described, it is obvious that many changes and modifications may be made thereunto, without departing from the spirit and scope of the invention.
. .
DESCRIPTION OF THE PREFERRED EMBODIMENT
The biodegradable polymer films to be used to inhibit fibrin fomlation and organization are materials which will eventually revert to the gel or solution state 5 and ultimately be resorbed and metabolized by the body. As taught in co-pending application Serial Number 07/644,758, these materials include amino N-carboxyalkyl derivatives of chitosan. Chitosan is a partially deacetylated chitin defined for the purposes herein as being greater than 50% deacetylated.
The N~arboxyalkyl derivatives used in the present invention are water soluble 10 polymers which have not been crosslinked to form insoluble materials. Specific examples of these materials are N-carboxymethyl chitosan, N~arboxybutyl chitosan, N,O carboxymethyl chitosan, and N,O-carboxybutyl chitosan, N-carboxy-ethyl chitosan, N,O-carboxyethyl chltosan, N,O-carboxypropyl chitosan, sulfated N-carboxyalkyl chitosan and N-carboxypropyl chitosan. However, these materials can be temporarily 15 insolubilized to form substances which will begin to degrade in a period of from 2-5 days to up to one year in vitto. It has been found that exposure of films of these materials to heat from 50C to 200C for various time periods varies the insolubilization time and ultimately the bioresorption time. In general, the higher the temperature of exposure and the longer the time of exposure, the greater the time to solubilize the film.
20 In order to vary the degradation time, the temperature and the length of time of heat exposure are varied from 50 - 200C anywhere from 20 minutes to 24 hours but could be as little as 10 minutes and preferably 10 minutes to ~ hours.
These materials are prepared from natural products or by ferrnentation methods ~;as described in U.S. Patents 4,835,265 and 4,619,995. The molecular weight of the 25 b~odegradable N-carboxyalkyl derivatives of chitosan for use in the present invention preferably range from 1,0Q0 daltons to 3,000,000 daltons.
In the preferred embociiment, these polymers would be in the form of a film, sponge, or woven sheet which will break down into visco-elasffc matenals. Examples .
of these would be the use of N,~carboxymethyl chitosan or N-carboxy-butyl chitosan ~30 films insolubilized by annealing with heat as described herein. While the exact -~ mechanism which causes the insolubillzation of the materials is unclear, it is postulated that either a dehydration mechanism, or a crystallization mechanism or a combination of the two is causing this phenomena. Additives such as anff-thrombogenic materiais, such as heparin or the like, may be added to the films before insolubilizing.
5~ Tl~E SHEE~
,~ ' '~'' '; ; ;
212`~02 -5- .
As described in co-pending application 07/644,758, it is also possible to form these materials into a viscous gel for injection into the affected location to prevent fibrinous buildup. This gel could be used for applications where a shorter ln vlvo residence time is desired and/or the location would best be suited for prevention 5 of adhesions with a material in this form. The gels may be formed by placing the insolubilized films in a sterile aqueous media and heating the solution to increased temperatures until the film hydrates and swells to form a gelatinous mass.
Again, as with the film, the degree of insolubilization of the viscous gels can be varied by varying the temperature of the aqueous solution and the extent of time 10 the film is allowed to remain in the solution.
The present invention has the added advantage that the insolubilization step canbe done during the heat or steam sterilization of the device, if desired. For example, the film may be insolubilized during the autoclave sterilization of the device at a temperature greater than 1 20C for a standard autoclave cycle.
The invention will now be described in further detail with reference being made to the following examples. It should, however, be recognized that the examples are given as being illustrative of the present invention and are not intended to define the spirit and spirit thereof.
20 Exam~le 1 . . .
One gram of medical grade N,O-carboxymethyl chitosan (NOVA Chern, Nova Scotia) was dissolved in 100 cc of purified water. The resulting 1% solution wasthen flltered through a series of cellulose membranes (12, 8, 0.45 micrometer) to remove all insoluble matter. The solution was then recirculated over and through a 0.5 25 micron tangential flow membrane which was specially treated with polypeptides specific for removal of pyrogen and other hydrophobic impurities (Catalog number 4200 -AlerChek, Portland, ME) for a period of approximately one hour on tangenttal flow ultra-flltration device (Filtron Non~ood, MA). The resumng solution was then rendered ~
of all low molecular weight impurities by extensive dialysis with water via a 300K
; 30 rnolecular weight cutoff membrane (Filtron - Norwood, MA) on the same ultra-filtration device.
Films were then formed from this solution by both casting (allowing evaporation)on a non-stick surface such as a glass petrii dish, or a plece of mylar fi1m and by freeze SUBgrITUl-E S~E~
drying by adding 300 ml of the solution to a 90 rnm diameter disposable petri dish and Iyophilized in a tray dryer for 72 hours a~ -50C. The resulting films (either cast or freeze dried~ were then insolubilized by placing the film into an oven at 121C for 20 minutes (correlating to a standard autoclave cycle). Both films were placed in aqueous media and dissolved within 5 days. Based on the dissolution which did occur, the film would dissolve in approximately two months.
Example 2 Three films were prepared as descnbed above in Example 1 by casting in a petri dish. Each was exposed to a different temperature for a period of 30 minutes. The first was heated at 76C, the second at 121C and the third.at 168C. One film was cast and not treated. This served as a control.
The four films were placed in ~ cc of PBS and placed in an incubator at 37C.
At various times, the samples were removed and obseNed yisually for solubility.
Followirig this the incubation medium was removed from the dish and analyzed forsoluble product via size exclusion chromatography. The control film was completely solubilized within one day. The film at 76C indicated complete solubility between 1-2 days. The 121 C treated film indicated complete solubility at 4-5 days, while the film treated at 168C indicated no evidence of solubility up to 14 days~
ExamPle ~
Three films were prepared as described above in Example 1 with the exception that the temperature of annealing was kept constant at 121C and the exposure time was varied between 15 minutes and 23 hours. Again, a non-treated film ser~Jed as a control. All films were evaluated as mentioned above.
The film treated at 15 minutes indicated complete solubility in 2-3 days, the film treated for 60 minutes indicated solubility through 14 days (complete solubility had not yet been attairied) while the film treated at 2 hours indicated no solubility in an excess of 14 days.
Thus the degradation of the films in wvo could be lengthened by increasing the annealing time and temperature. For a typical orthopedic application, a film which would degrade within 14 days is desirable and may be attained by annealing at 121C
for about 60 minutes~
TITl,~TF S~
2i25~02 The material of the present invention may be used in a nnethod for preventing adhesions between soft intemal body tissue by first preparing an aqueous solution of N-carboxyalkyl derivatives of chitosan, then forming a film from the aqueous solution by removing water therefrom and then insolubilizing the film by heating the film at a 5 temperature of at least 70C for a minimum of 15 minutes and placing the film between the tissues after being insolubilized.
While several examples of the present invention have been described, it is obvious that many changes and modifications may be made thereunto, without departing from the spirit and scope of the invention.
. .
Claims (13)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for temporarily insolubilizing anti-adhesive films made from N-carboxyalkyl derivatives of chitosan by heating the films at a temperature between 50°C and 200°C for a predetermined time period of from 10 minutes to 24 hours.
2. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N,O-carboxymethyl chitosan.
3. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N-carboxymethyl chitosan.
4. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N,O-carboxyethyl chitosan.
5. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N-carboxyethyl chitosan.
6. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N,O-carboxybutyl chitosan.
7. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is N-carboxybutyl chitosan.
8. The method as set forth in claim 1 wherein the derivative of N-carboxyalkyl chitosan is sulfated N carboxyalkyl derivatives of chitosan.
9. The method as set forth in claim 1 wherein the film is formed by casting an aqueous solution of said N-carboxyalkyl derivatives of chitosan on a flat surface and evaporating the aqueous media.
10. The method as set forth in claim 1 wherein said film is formed by placing an aqueous solution of said N-carboxyalkyl derivatives of chitosan in a mold and lyophilizing.
11. The method as set forth in claim 1 wherein the film includes an anti-thrombogenic agent.
12. The method as set forth in claim 1 wherein the film is insolubilized during the autoclave sterilization of the device at a temperature of greater than 120°C for a standard autoclave cycle.
13. A method for producing a film adapted for preventing adhesions between soft internal body tissues, comprising the steps of:
preparing an aqueous solution of N-carboxyalkyl derivatives of chitosan;
forming a film from the aqueous solution by removing the water therefrom; and temporarily insolubilizing the film by heating the film at a temperature of at least 76°C for a minimum of fifteen minutes.
preparing an aqueous solution of N-carboxyalkyl derivatives of chitosan;
forming a film from the aqueous solution by removing the water therefrom; and temporarily insolubilizing the film by heating the film at a temperature of at least 76°C for a minimum of fifteen minutes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81218791A | 1991-12-20 | 1991-12-20 | |
| US07/812,187 | 1991-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2125402A1 true CA2125402A1 (en) | 1993-07-08 |
Family
ID=25208800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002125402A Abandoned CA2125402A1 (en) | 1991-12-20 | 1992-12-08 | Process for insolubilizing n-carboxyalkyl derivatives of chitosan |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0617707A1 (en) |
| JP (1) | JPH0826081B2 (en) |
| AU (1) | AU3235593A (en) |
| CA (1) | CA2125402A1 (en) |
| WO (1) | WO1993013137A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5931165A (en) * | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
| US5888988A (en) * | 1995-05-08 | 1999-03-30 | Chitogenics, Inc. | Covalently linked N,O-carboxymethylchitosan and uses thereof |
| US5679658A (en) * | 1995-05-08 | 1997-10-21 | Chitogenics, Inc. | N,O-carbonxymethylchitosan for prevention of surgical adhesions |
| US5791352A (en) * | 1996-06-19 | 1998-08-11 | Fusion Medical Technologies, Inc. | Methods and compositions for inhibiting tissue adhesion |
| US6645947B1 (en) * | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
| US7265097B2 (en) | 2002-08-20 | 2007-09-04 | Chitogenics, Inc. | Methods of drug delivery using sulphated chitinous polymers |
| FR2844717B1 (en) * | 2002-09-23 | 2006-07-07 | Richard Cancel | REINFORCING PLATE COMPRISING IN PARTICULAR CHITOSAN |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4326523A (en) * | 1980-08-25 | 1982-04-27 | International Minerals & Chemical Corp. | Method of supplying micronutrients to animals |
| US4619995A (en) * | 1984-12-24 | 1986-10-28 | Nova Chem Limited | N,O-carboxymethyl chitosan and preparative method therefor |
| ES2066152T3 (en) * | 1989-10-31 | 1995-03-01 | Howmedica | COMPOSITIONS CONTAINING DERIVATIVES OF CHITIN TO PREVENT ACCESSION. |
-
1992
- 1992-12-08 JP JP5511669A patent/JPH0826081B2/en not_active Expired - Lifetime
- 1992-12-08 EP EP93900814A patent/EP0617707A1/en not_active Withdrawn
- 1992-12-08 AU AU32355/93A patent/AU3235593A/en not_active Abandoned
- 1992-12-08 WO PCT/US1992/010417 patent/WO1993013137A1/en not_active Application Discontinuation
- 1992-12-08 CA CA002125402A patent/CA2125402A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06511279A (en) | 1994-12-15 |
| WO1993013137A1 (en) | 1993-07-08 |
| AU3235593A (en) | 1993-07-28 |
| EP0617707A1 (en) | 1994-10-05 |
| JPH0826081B2 (en) | 1996-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5093319A (en) | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions | |
| EP0426368B1 (en) | Compositions containing derivatives of chitin for preventing adhesion | |
| EP0648122B1 (en) | PREVENTING TISSUE ADHESION USING $i(IN SITU) MODIFICATION OF ALGINATE | |
| WO1993013136A1 (en) | Ultra-pure polysaccharide materials for medical use | |
| CA2377544C (en) | Hyaluronic acid anti-adhesion barrier | |
| KR100374666B1 (en) | Hyaluronic acid gel, process for producing the same and medical material containing the same | |
| KR100395724B1 (en) | Hard Tissue Stimulating Agent | |
| US5462976A (en) | Photocurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof | |
| GB2314842A (en) | Protein/oxidised regenerated cellulose complexes | |
| CN100379462C (en) | Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same | |
| US20090214667A1 (en) | Medical technical product, method for producing the same and providing the same for surgery | |
| JP3955107B2 (en) | Method for producing crosslinked polysaccharide | |
| CA2125402A1 (en) | Process for insolubilizing n-carboxyalkyl derivatives of chitosan | |
| JP4690892B2 (en) | Antiadhesive material for spine and spinal cord surgery | |
| JP3420851B2 (en) | Anti-adhesion agent | |
| JP2003019194A (en) | Co-crosslinked gel composition comprising hyaluronic acid and carboxymethyl cellulose | |
| Widiyanti et al. | Development of Aldehyde Hyaluronic Acid-N, O-Carboxymethyl Chitosan based Hydrogel for Intraperitoneal Antiadhesion Application | |
| AU696183C (en) | Hard tissue stimulating agent | |
| BRPI0905514A2 (en) | chitosan and hydroxyapatite (cnhap) biomaterial for bone filling and process for bone production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |